glp.1 GLP-1 Drug Side Effects May Be Tackled with More Mechanistic Studies Bariatric Fusion GLP Who Should Explore GLP-1 Shots

Muller TD, Clemmensen C, Finan B, DiMarchi RD, Tschop MH

When sotaglifozin was administered (30 mg/kg/d for 6 weeks) in obese rats, with metabolic-syndrome-related models of HF with HFpEF, and wild-type rats, this treatment ameliorated left atrial enlargement in HFpEF in vivo, prevented mitochondrial swelling, enhanced mitochondrial Ca 2+ buffer capacity in HFpEF, improved mitochondrial fission and reactive oxygen species (ROS) production during glucose starvation, and averted Ca 2+ accumulation upon glycolytic inhibition [122]

doi: 10.3390/medicina57070669

Novo Nordisk press release Montes Claros Brazil investment April 2025

The demographic distribution of those most likely to stop treatment was as follows: patients of color, men, people enrolled in Medicare or Medicaid, those living in areas with very high social needs, heart failure, obesity or other cardiovascular diseases prior to drug initiation, and those experiencing new gastrointestinal adverse effects at follow-up [132]